Sydney Head and Neck Cancer Institute, The Sydney Cancer Centre, Royal Prince Alfred Hospital, New South Wales, Sydney, Australia.
Head Neck. 2013 Aug;35(8):1144-8. doi: 10.1002/hed.23102. Epub 2012 Aug 21.
There is a small subgroup of patients with head and neck cutaneous squamous cell carcinoma (cSCC) in which nodal metastases present concurrently with the primary lesion. There is evidence that these tumors may represent a more aggressive subset of cSCC. The aim of this study was to determine whether alternative clinicopathologic prognostic factors should be applied to this patient cohort.
A retrospective analysis of data from prospective databases of 2 large head and neck cancer units in Sydney, Australia, was performed. Ninety-five patients with concurrent primary and nodal metastatic head and neck cSCC were suitable for inclusion in the study.
Univariable analysis was performed for overall survival (OS) and disease-specific survival (DSS). OS was adversely affected by immunosuppression (p = .011) and nodal extracapsular spread (ECS) (p = .006). Similarly, immunosuppression (p = .005) and ECS (p = .005) indicated a worse outcome for DSS. ECS and immunosuppression remained significant in the multivariable analysis.
This study found that adverse prognostic factors were similar to the current evidence for nonconcurrent metastatic cSCC. In particular, the primary lesion had no significant influence on survival.
有一小部分头颈部皮肤鳞状细胞癌(cSCC)患者,其淋巴结转移与原发性病变同时出现。有证据表明,这些肿瘤可能代表更具侵袭性的 cSCC 亚群。本研究旨在确定是否应将替代临床病理预后因素应用于这组患者。
对澳大利亚悉尼 2 个大型头颈部癌症中心前瞻性数据库中的数据进行回顾性分析。95 例同时患有头颈部 cSCC 原发性和淋巴结转移性的患者适合纳入本研究。
对总生存率(OS)和疾病特异性生存率(DSS)进行单变量分析。免疫抑制(p =.011)和淋巴结外囊扩散(ECS)(p =.006)对 OS 有不利影响。同样,免疫抑制(p =.005)和 ECS(p =.005)也表明 DSS 的预后更差。在多变量分析中,ECS 和免疫抑制仍然是显著的预后因素。
本研究发现,不良预后因素与非同时性转移性 cSCC 的现有证据相似。特别是,原发性病变对生存率没有显著影响。